AI Blood Assay Detects Liver Cancer Across Diverse International Populations

Our latest study in Cell Press Blue shows how an AI-enabled, cfDNA fragmentome-based blood test can provide a high-performing, accessible approach to detecting liver cancer across diverse populations and disease etiologies. Across 377 individuals from geographically distinct cohorts in Guatemala and Romania, we demonstrated high performance of our locked fragmentome classifier for detection of early-stage liver cancer. We also developed a new tissue-of-origin approach, MethID, that found that fragmentomes reflect not only tumor and liver cells, but also vascular and immune responses to cancer. Congrats to Hope, Carter, Shashi, Zack and all members of our team on these exciting findings that highlight the potential of the cfDNA fragmentome for both early cancer detection and understanding disease biology!

Orjuela H, Norton C, Koul S, Bruhm DC, Annapragada, AV, Zavras J, Short S, Boyapati K, Bartolomucci A, Adleff V, Vulpescu NA, Lebarbenchon KP, Carey J, Portwood C, Sorop A, Iacob R, Iacob S, Gheorghe L, Dima S, Ramírez-Zea M, McGlynn K, Phallen J, Scharpf RB, Groopman J, Velculescu VE, Foda ZH. Detection and characterization of hepatocellular carcinoma using cfDNA fragmentomes. Cell Press Blue. 2026 Jul 31. Epub ahead of print. Article | Press.

Social tagging: > > >

Comments are closed.